Drs L.E. Hillege, M.D.

Dieleman, S., Bruggeling, C., Le, P. D., Hillege, L. E., Correia Tavares Bernardino, C., Ziemons, J., Cremers, R., Jacquerie, A., Gusinac, A., Ederveen, T. H. A., Verrijp, K., Penders, J., Vos, A.-M., Kooreman, L. F. S., Grabsch, H. I., Smidt, M. L., & Boleij, A. (2026). Impact of neoadjuvant chemotherapy on local breast microbiota and macrophages in ER-positive breast cancer with links to treatment response. npj Breast Cancer, 12(1), Article 141. Advance online publication. https://doi.org/10.1038/s41523-026-01004-0

Heuvelings, D. J. I., Hillege, L. E., Al-Taher, M., & Schols, R. M. (2025). Potential of methylene blue fluorescence angiography for multiple intraoperative tissue perfusion assessments in plastic and reconstructive surgery: current knowledge and prospects. Frontiers in Surgery, 12, Article 1681731. https://doi.org/10.3389/fsurg.2025.1681731

Russ, E., Ziemons, J., Hillege, L. E., van Kuijk, S. M. J., de Jong, E. M., Elbers, C., Deenen, M. J., Borghuis, L. H., Bohm, T. M. M., Kristen, P., Valk, L. C., van Hellemond, I. E. G., Vestjens, H., Dietvorst, A., Baars, A., Goosens, A. N. M., Vermeulen, L., Buffart, T. E., de Vos-Geelen, J., ... Smidt, M. L. (2025). Evaluation of potential biomarkers during irinotecan-based systemic treatment for colorectal cancer-study protocol of the OPTIMA study. BMC Cancer, 25(1), Article 1129. https://doi.org/10.1186/s12885-025-14500-6

Hillege, L. E., Trepka, K. R., Guthrie, B. G. H., Fu, X., Aarnoutse, R., Paymar, M. R., Olson, C., Zhang, C., Ortega, E., Ramirez, L., de Vos-Geelen, J., Valkenburg-van Iersel, L., van Hellemond, I. E. G., Baars, A., Vestjens, J. H. M. J., Penders, J., Deutschbauer, A., Atreya, C. E., Kidder, W. A., ... Turnbaugh, P. J. (2025). Microbial vitamin biosynthesis links gut microbiota dynamics to chemotherapy toxicity. Mbio, 16(6). https://doi.org/10.1128/mbio.00930-25

Hillege, L. E., Barnett, D. J. M., Ziemons, J., Aarnoutse, R., de Vos-Geelen, J., van Geel, R., de Boer, M., van Riet, Y. E. A., Vincent, J., Penders, J., & Smidt, M. L. (2025). The gut microbiota during tamoxifen therapy in patients with breast cancer. Scientific Reports, 15(1), Article 7874. https://doi.org/10.1038/s41598-025-91734-1

Hillege, L. E., Stevens, M. A. M., Kristen, P. A. J., de Vos-Geelen, J., Penders, J., Redinbo, M. R., & Smidt, M. L. (2024). The role of gut microbial β-glucuronidases in carcinogenesis and cancer treatment: a scoping review. Journal of Cancer Research and Clinical Oncology, 150(11), Article 495. https://doi.org/10.1007/s00432-024-06028-2

Ziemons, J., Hillege, L. E., Aarnoutse, R., de Vos-Geelen, J., Valkenburg-van Iersel, L., Mastenbroek, J., van Geel, R., Barnett, D. J. M., Rensen, S. S., van Helvoort, A., Dopheide, L. H. J., Roeselers, G., Penders, J., Smidt, M. L., & Venema, K. (2024). Prebiotic fibre mixtures counteract the manifestation of gut microbial dysbiosis induced by the chemotherapeutic 5-Fluorouracil (5-FU) in a validated in vitro model of the colon. BMC Microbiology, 24(1), Article 222. https://doi.org/10.1186/s12866-024-03384-4

Dieleman, S., Hillege, L., Ziemons, J., Kooreman, L., Penders, J., Boleij, A., Grabsch, H., & Smidt, M. (2023). Microbiota immuuninteracties bij kankerontwikkeling en behandeling. Nederlands Tijdschrift voor Leefstijlgeneeskunde, 1(4), 177-182.